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Abstract
Objectives
The objective of this study was to evaluate to evaluate the role of mannose-binding-lectin
deficient genotypes in pneumococcal meningitis (PM) in children.
Methods
We performed a 16-year retrospective study (January 2001 to March 2016) including
patients 18 years with PM. Variables including attack rate of pneumococcal serotype
(high or low invasive capacity) and MBL2 genotypes associated with low serum MBL levels
were recorded.
Results
Forty-eight patients were included in the study. Median age was 18.5 months and 17/48 epi-
sodes (35.4%) occurred in children 12 months old. Serotypes with high-invasive disease
potential were identified in 15/48 episodes (31.2%). MBL2 deficient genotypes accounted
for 18.8% (9/48). Children 12 months old had a 7-fold risk (95% CI: 1.6–29.9; p < 0.01) of
having a MBL2 deficient genotype in comparison to those > 12 months old. A sub-analysis
of patients by age group revealed significant proportions of carriers of MBL2 deficient geno-
types among those 12 months old with PM caused by opportunistic serotypes (54.5%),
admitted to the PICU (Pediatric Intensive Care Unit) (46.7%) and of White ethnicity (35.7%).
These proportions were significantly higher than in older children (all p<0.05).
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Conclusions
Our results suggest that differences in MBL2 genotype in children12 months old affects
susceptibility to PM, and it may have an important role in the episodes caused by non-high
invasive disease potential serotypes.
Introduction
Streptococcus pneumoniae remains a serious health problem and a leading cause of life-threat-
ening invasive infection in young children. More than 14 million cases of pneumococcal
disease occur annually in children aged< 5 years with a mortality rate over 5% [1]. S. pneumo-
niae is the main cause of bacterial meningitis in children beyond the neonatal period [1]. The
morbility and case-fatality ratio for pneumococcal meningitis is high. The average global pneu-
mococcal meningitis case-fatality ratio has been estimated to be 59%” [1].
Children are often colonized with S. pneumoniae in the nasopharynx. Capsular polysaccha-
rides are the main virulence factors of pneumococci. There are more than 95 different capsular
types (serotypes) but not all have the same ability to invade and cause disease. Some S. pneumo-
niae serotypes are considered to have a low-invasive capacity to cause disease and are often
found in carriers. They are common colonizers specially in children < 2 years and have more
temporal opportunity for invasion in this age range. They are also called “opportunistic sero-
types” [2,3]. In contrast, serotypes with a high-invasive capacity to cause disease are seldom
detected in carriers but they are an important cause of invasive disease specially in older chil-
dren [4,5]. Serotypes are classified according to the studies of Brueggemann [4] Sleeman [5]
and del Amo [6]: 1, 4, 5, 7F, 8, 9V, 12F, 14, 18C and 19A are considered to have a high-attack
rate or highly-invasive serotypes whereas the remainder are considered as low-attack rate or
non-highly-invasive or opportunistic serotypes. These highly-invasive serotypes are generally
included in the pneumococcal vaccines (PCV13 or PPSV23).
The complex interaction between impaired host immune factors and virulence determi-
nants of the pneumococcus plays a role in the development of invasive pneumococcal disease
(IPD) [7]. Components of the host innate immune response are important first-line defense
factors against infections in young children since the adaptive response is still developing and
often altered with reduced antibody response and of shorter persistence [8]. Mannose-binding
lectin (MBL) is a proinflammatory protein of the innate immune system involved in comple-
ment activation via the lectin pathway and it provides immediate host defense against infection
[9]. Current knowledge holds that MBL serum levels largely depend on the MBL2 genotype
[10–12]. MBL has the capacity of activating the complement cascade independent of antibody
response [9] and its plasma concentration is genetically determined [13,14]. S. pneumoniae
shows low to intermediate MBL binding capacity and MBL-deficiency has been associated
with a 5-fold increased risk of death due to pneumococcal disease [15].
Evidence supports MBL-deficiency as a risk factor for developing IPD [9], higher risk of
developing severe respiratory complications in neonates and young children [16], higher bac-
terial loads during meningococcal sepsis in young children [17], and increased risk for higher
frequency and duration of infectious complications in children with malignancies [18]. How-
ever, its role in host defense to pneumococcus remains a matter of debate. It has been consid-
ered to predispose to IPD for some authors, while others have discarded it [9,19,20].
The objective of the present study is to evaluate PM susceptibility in pediatric patients con-
sidering the major virulence factor of pneumococci, capsular type and the genetic variation
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within the MBL2 gene as an important host immune factor. This information could be useful
for designing preventive strategies on children based on previous analysis of host-pathogen
interactions.
Materials and methods
Setting, population and design
The Pediatric Pneumococcal Surveillance Study Group based at Hospital Sant Joan de Deu
(Barcelona) has been prospectively collecting epidemiological, clinical and analytical data
from children with IPD since 1988. In this retrospective observational study we included
patients 18 years of age with community acquired PM from our database between 1 January
2001 and 31 March 2016 (conjugated vaccine era). Children were classified in <12 months of
age and>12 months of age. PM was defined as an S. pneumoniae positive cerebrospinal fluid
(CSF) culture and/or S. pneumoniae DNA detection in CSF.
Microbiologic methods
Pneumococcal isolates were identified and serotyped using standard methods in the molecular
microbiology department at Hospital Sant Joan de Deu. DNA detection of pneumolysin (ply)
and LytA gene by Real-Time PCR (polymerase chain reaction) in CSF was performed according
to previously reported assays [21–24].
Serotypes were classified according to published scientific assays [4–6]: 1, 4, 5, 7F, 8, 9V,
12F, 14, 18C and 19A were considered as high-attack rate or highly-invasive serotypes whereas
the remainder were considered as low-attack rate or non-highly-invasive or opportunistic
serotypes.
MBL2 polymorphism analysis
DNA extraction, amplification and genotyping of MBL2 were carried out as previously
described [25]. Six single nucleotide polymorphisms (SNPs) in the 5’-flanking/promoter
region (-550 G/C -221 C/G, 4 C/T) and the exon 1 (codon 52 CGT/TGT, codon 54 GGC/GAC
and codon 57 GGA/GAA) of the MBL2 gene were analyzed using a PCR and Sequence-Based
Typing (SBT) technique. The D, B and C variants at codons 52, 54 and 57, respectively, are
major determinants of low serum MBL levels [13]. As previously described by Ali YM et al
[20], these variants are collectively named O, while A indicates the wild-type variant at all
those codons. The SNPs at positions –551 [H/L], −221 (X/L) and +4 (P/Q) also influence
serum MBL levels in individuals with the wild-type A variant. However, the functional effects
of H/L and P/Q SNPs appear to be minor compared to L/X, X being the allele associated with
lower MBL expression. Accordingly, MBL serum concentrations can be divided into the fol-
lowing 3 genotype groups: high (A/A, A/XA), intermediate (XA/XA, A/O) and low (XA/O,
O/O).
Data collection and exclusion criteria
Clinical information of patients was extracted from medical records and recorded on a stan-
dardized case report form that included demographics, clinical presentation, laboratory
results, neuroimaging findings, management, complications and neurological sequelae. Chil-
dren with functional deficit of classical or alternative pathways of complement activation were
excluded from the study, as well as patients with immunocompromised conditions (human
immunodeficiency virus infection, immunoglobulin deficits), cystic fibrosis, bronchiectasis or
cerebrospinal leak.
MBL2 deficient genotypes and pneumococcal meningitis
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Statistical analysis
Statistical analysis was performed using Statistical Package for Social Sciences Software (IBM
SPSS1 22 version). Descriptive statistics was used to characterize the study population. The χ2
test and Fisher exact test were used to compare categorical variables. Continuous non-nor-
mally distributed variables were described in terms of median value with interquartile range
(IQR, 25th percentile - 75th percentile) and compared using Mann-Whitney U test. Risk associ-
ations are presented as relative risk with 95% confidence intervals. A 2-tailed P value<0.05
was considered statistically significant.
Data confidentiality and ethical aspects
All information collected was treated as confidential in strict observance of legislation. The
study was approved by the Ethics Committee of Hospital Sant Joan de Deu (Permit Number:
CEIC PIC 98–13) and conducted according to the principles expressed in the Declaration of
Helsinki. All subjects and their legal representatives included in the study received detailed
information about the aims of the study prior to recruitment. Written informed consent was
obtained from all patients/legal representatives.
Results
Characteristics of the study population
A total of 821 IPD episodes occurred during the study period; 104 PM episodes (12.7%) were
identified among 93 children (29/93, 27.9% were<12 months). 12/104 episodes (11.5%) were
excluded due to exclusion criteria [cerebrospinal leak]; 33/104 episodes (31.7%) refused to par-
ticipate in the study. 8/104 children (7.7%) died due to the infection. All of the patients who
died but one were under 2 years of age. They were mainly male (75%). The pneumococcal
strain was serotyped in 5 of the patients (4/5 were opportunistic serotypes). Among those that
were serotyped, all but one are included in the 13v pneumococcal vaccine. No MBL genotypes
were available for those patients. Thus, the final study sample comprised 48 episodes with PM.
There was a predominance of males (29/48; 60.4%). The predominant ethnic group was
White (43/48; 89.6%). Median age was 18.5 months (IQR, 7.2–54.2) and 17/48 episodes
(35.4%) occurred in children 12 months old. There was a median LOS of 17 days (IQR, 13–
24). In 43/48 episodes (89.6%) admission to the Pediatric Intensive Care Unit (PICU) was
required. Only 15/48 patients (31.2%) had previously been completely vaccinated (10 with
PCV7 and 5 with PCV13); 31/48 (64.6%) suffered sequelae (such as motor impairment, sei-
zures, psychomotor retardation, hearing loss or loss of vision). Table 1 shows demographic,
clinical and microbiological variables of patients according to age category.
Diagnosis and serotyping
Among all episodes, 35.4% (17/48) were confirmed only by PCR, 20.8% (10/48) by culture and
43.8% (21/48) by both PCR and culture. No patient was positive for any other bacteria other
than S.pneumoniae in CSF or blood cultures or PCR analysis. Capsular serotypes were available
for all PM cases. Serotypes 19A, 19F and 3 were the most frequent serotypes and accounted for
about 31.2% of the infections (19A, n = 5/48; 19F, n = 5/48 and 3, n = 5/48). Serotypes with
high-invasive capacity were identified in 15/48 episodes (31.2%). The currently used PCV13
vaccine would have covered 62.5% of serotypes that caused PM (30 out of 48 episodes). Geno-
type of MBL2 gene was available for all 48 patients. Deficient-MBL associated genotypes
accounted for 18.8% (9/48). Table 2 provides an overview of haplotype frequencies.
MBL2 deficient genotypes and pneumococcal meningitis
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Median age in patients with MBL2 deficient genotypes was 8.0 months (IQR 4.0–15.5) com-
pared to 44.5 months (IQR 10.0–67.0) in patients with MBL2 non-deficient genotypes (p =
0.01). Children 12 months old had a 7-fold risk of having a low-MBL genotype in compari-
son to those > 12 months old (Relative-Risk = 7.00 (95% CI: 1.6–29.9; p< 0.01). A sub-analy-
sis of patients by age category (considering children’s age at the cut-off value of 12 months old)
revealed significant proportions of carriers of MBL2 deficient genotypes among those 12
months old with PM caused by opportunistic serotypes (54.5%, 6/11), admitted to the PICU
(46.7%, 7/15) and of white ethnicity (35.7%, 5/14). These proportions were significantly higher
than in older children (p< 0.05) (Table 3).
MBL2 deficient genotypes were not found to be significantly associated with sex, ethnicity,
serotype invasiveness, PICU admission, vaccination status or clinical course variables. Data
regarding associations between variables and MBL2 genotypes are presented in Table 4.
Discussion
This study highlights the relationship between genetically determined MBL deficiency and the
increased risk of pneumococcal meningitis in children younger than 12 months old, especially
by serotypes with low invasive capacity or opportunistic serotypes.
Susceptibility to IPD is higher in younger children [1,2]. Children under 2 years of age rely
on their innate immune response to overcome infections, which is critical to avoid the spread
of nasopharyngeal colonizing organisms into sterile human body sites [8]. MBL is a circulating
Table 1. Demographic, clinical and microbiological variables of patients according to age category.
Characteristics 12 months >12 months Total p-value
Subjects 17 31 48
Male 12 (70.6) 17 (54.8) 29 (60.4) 0.29
White Ethnicity 14 (82.3) 29 (93.5) 43 (89.6) 0.22
PICU admission 15 (88.2) 28 (90.3) 43 (89.6) 0.82
LOS days [IC95%] 20.8 (15.4–26.1) 25.2 (9.4–41.2) 0.75
Sequelae 8 (47.1) 23 (74.2) 31 (64.6) 0.06
Non-vaccinated according to age 11 (64.7) 22 (71.0) 33 (68.8) 0.65
PM caused by low invasive serotypes 11 (64.7) 22 (71.0) 33 (68.7) 0.65
PCV13 serotypes 10 (58.8) 20 (64.5) 30 (62.5) 0.70
MBL2 deficient genotypes 7 (41.2) 2 (6.4) 9 (18.7) 0.03
PICU, pediatric intensive care unit; LOS, length of stay; PM, pneumococcal meningitis; PCV13, 13-valent pneumococcal vaccine; MBL, mannose-binding-
lectin
Significant values in bold numbers
https://doi.org/10.1371/journal.pone.0178377.t001
Table 2. Overview of haplotypes frequencies in children with pneumococcal meningitis.
YY YX XX
AA A/A n = 15 (31.3%) A/XA n = 10 (20.8%) XA/XA n = 4 (8.3%)
AO A/O n = 10 (20.8%) XA/O n = 4 (8.3%)
OO O/O n = 5 (10.4%)
MBL serum concentrations were divided into the following 3 groups: normal (A/A, A/XA), intermediate (XA/
XA, A/O) and deficient (XA/O, O/O). Mannose-binding-lectin (MBL) protein expression: white: normal; light
grey: intermediate; dark grey: defective.
https://doi.org/10.1371/journal.pone.0178377.t002
Promoter
Exon
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protein of the innate immune system and its deficiency has been reported to predispose to IPD
[9]. A previous study of our group suggested that a genetically determined low-MBL produc-
tion could be associated with IPD when disease occurs in children under 2 years of age [24]. In
the present study, we also found a significantly higher proportion of MBL2 deficient genotypes
among children 12 months with PM. The frequency of MBL2 deficient genotypes was signif-
icantly higher in children12 months of age in comparison to older patients (41.1% vs 6.2%),
whereas the overall MBL2 deficient genotypes prevalence in adults from our setting is around
10–15% [26]. These data suggest that children with MBL2 deficient genotypes are at higher
risk of PM in their first year of life. This is in agreement with Brouwer et al report on associa-
tion of low-producing MBL2 genotypes and increased risk of PM [27].
On the other hand, IPD in children is often caused by serotypes with low invasive disease
potential [3], as we report in our series (68.8% of the PM were caused by opportunistic sero-
types). Considering only the episodes caused by opportunistic serotypes, we observed that the
proportion of individuals with MBL2 deficient genotypes was higher in children 12 months
old than in older ones. Nevertheless, this finding was not observed in those children with PM
caused by high-invasive disease potential. In our opinion, this suggests that low invasive capac-
ity serotypes may have more opportunities to cause invasive disease in young children with
MBL2 deficient genotypes as their immunity relies specifically in the innate immune system.
In our previous study, the frequency of MBL2 deficient genotypes was especially high in
Table 3. Variable frequencies according to age group and MBL2 genotype.
Age group12
months
Age group > 12
months
Variables Total number of
patients
Patients with MBL2 deficient
genotypes
Total number of
patients
Patients with MBL2 deficient
genotypes
p-
value*
Serotype invasiveness
Opportunistic serotype 11 6 (54.5%) 22 1 (4.55%) < 0.01
High invasiveness 6 1 (16.6%) 9 1 (11.1%) 0.76
White ethnicity 14 5 (35.7%) 29 2 (6.9%) 0.02
Clinical course with
sequelae
8 3 (37.5%) 23 2 (8.7%) 0.06
PICU admission 15 7 (46.7%) 28 2 (7.1%) <0.01
Significant values in bold numbers.
MBL, mannose-binding-lectin; PICU, pediatric intensive care unit.
* Proportions between groups were compared using Pearson Chi-square test or Fisher’s exact test when appropriate
https://doi.org/10.1371/journal.pone.0178377.t003
Table 4. Variable frequencies according to MBL2 genotype.
Variables Patients with MBL2 deficient genotypes Patients with MBL2 non-deficient genotypes p value
Age [months], IQR 8.0 (4.0–15.5) 44.5 (10.0–67.0) 0.01
Female 5 (55.6) 14 (35.9) 0.27
White ethnicity 7 (77.8) 36 (92.3) 0.19
PICU admission 9 (100) 34 (87.2) 0.25
LOS days (SD) 26.56 (±24.79) 20.28 (±13.27) 0.29
Clinical Course with sequelae 5 (55.6) 26 (66.7) 0.53
Non-high invasiveness / opportunistic serotype 7 (77.8) 26 (66.7) 0.51
Data are presented as n (%). IQR (interquartile range)
Significant values in bold numbers
PICU, pediatric intensive care unit; LOS, length of stay; SD, standard deviation
https://doi.org/10.1371/journal.pone.0178377.t004
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younger children with IPD caused by opportunistic serotypes too [24]. At this point, it is
important to underline that 13-valent conjugated vaccine would have protected against the
main serotypes causing PM in our series, achieving protective antibody titers with prompt vac-
cination schedules [28].
A potential limitation in this study could be the assumption that patients were healthy prior
to meningitis. Some of the children might have unidentified immunodeficiency or other
chronic diseases that had not been diagnosed at the time of meningitis. However we have tried
to lower this bias through the exclusion criteria and long follow-up. Secondly, the role of other
protein receptors such as ficolins, pentraxins or salivary agglutinin/gp340/DMBTI known to
be involved in the innate immune system response to S. pneumonia has not been studied [29].
Third, we did not analyze other factors that may be involved in the set from colonization to
disease and, in particular, the role of co-infection with respiratory viruses [30,31]. Fourth, if
the sample size was larger the difference between the conditions compared could be measured
with greater confidence. However, this is harder to achieve in pediatric studies.
In conclusion, the importance of MBL in susceptibility to infection is largely discussed and
remains controversial [9,19,20,32], but our results suggest that genetic variation in the MBL2
gene could affect the susceptibility to PM in children12 months old, and it may have a more
important role in the episodes caused by non-high invasive disease potential serotypes. This
association suggests that the risk of IPD cannot only be assessed by clinical, epidemiological or
microbiological factors but also by the immune characteristics of the youngest hosts. In this
regard, the conceptual framework known as PIRO (predisposition, infection characteristics,
host response and organ dysfunction) [33] could be a tool not only for understanding the
physiopathology of meningitis but also for helping to better the prognosis and be able to design
appropriate interventions and evaluate the impact that they represent. We believe that know-
ing what factors are most important for morbidity and mortality in our patients may help to
stratify risk and improve the use of health resources. Children with the risk factors noted
above may be more aggressively monitored and treated and preventive strategies, such as early
vaccination, strongly recommended.
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